Carematrix Pre-Commercial Procurement (PCP)

This contract notice invites interested operators to submit tenders to a procurement.

The procurement aims to trigger new solutions to be developed and tested to address the following challenge: To anticipate and address the needs of people suffering from multimorbititiy, by ensuring timely service access, co-managed care journeys and transitions between specialties and sectors. It will address the white spaces between silo-based single-diagnosis treatment tracks, and the white spaces occurring in caregiver transitions. Some of the main technical challenges to be addressed are: 20 % reduction in time spent for visits to care facilities and increased patient safety by 50 % fewer inter-organisational patient data-related incidents.

This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Huvudsaklig plats för byggnation/anläggning eller utförande: Main site or place of performance: Testing is expected to take place at the procurers' sites: Basque country(ES), Oslo-Viken (NO) and Skåne (SE).

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases.

The 3 phases are:

-R&D up to solution design

-R&D up to a prototype

-R&D up to original development, validation and testing of a limited set of first products or services.

After each phase, intermediate evaluations will be carried out to progressively select the best of the competingsolutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the nextphase.

Testing is expected to take place in Basque country(ES), Oslo-Viken (NO) and Skåne (SE). This testing mayalso serve as a first customer test reference for the contractors. The procurement is expected to start inmarch-23 and end in september-25.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate duringthe PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyondthe procurers. The market potential is estimated at EUR 75 000 000 000 (across Europe).

Award criteria:

Price is not the only award criterion and all criteria are stated only in the procurement documents

This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme, under grant agreement No 964370 — Carematrix PCP (see carematrix.eu). The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs.

Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

More information:

See:

- the project website (carematrix.eu)

- the open market consultation material (https://carematrix.eu/open-market-consultation/)

Participation in the open market consultation (OMC) that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender. All material and recordings from the OMC are publicly available at carematrix.eu

Mercell notice: https://opic.com/id/afpxmqvydp